Sign In
Buy NPCE
$15.88
-0.410 (-2.52%)
At Close: Jun 03, 2026
NeuroPace Reports Third Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance
04:03pm, Monday, 06'th Nov 2023
Third quarter 2023 revenue of $16.4 million, an increase of 47% year-over-year Full-year revenue guidance increased to $62.5-$63.5 million, up from $59-$61 million Cash burn reduced to $2.2 million in
NeuroPace Announces RNS System Enhancements Designed to Streamline Care
04:05pm, Tuesday, 17'th Oct 2023
- Upgraded nSight Platform Improves Clinicians' Ability to Track, Review and Evaluate Patient Data - - ‘Simple Set Programming' Enables Complete Programming Set Transfer Directly to RNS Tablet - - F
NeuroPace to Report Third Quarter 2023 Financial Results on November 6, 2023
05:01pm, Monday, 16'th Oct 2023
MOUNTAIN VIEW, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, tod
NeuroPace to Participate in 2023 Cantor Fitzgerald Global Healthcare Conference
04:05pm, Wednesday, 20'th Sep 2023
MOUNTAIN VIEW, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, to
NeuroPace: A Speculative Epilepsy Play
05:22am, Tuesday, 05'th Sep 2023
NeuroPace aims to improve the lives of epilepsy patients with its remote monitoring system. The company's RNS system offers personalized and real-time treatments for epilepsy patients. NeuroPace has s
NeuroPace to Participate in Upcoming Investor Conferences
04:05pm, Thursday, 24'th Aug 2023
- Wells Fargo 2023 Healthcare Conference - - Morgan Stanley 21 st Annual Global Healthcare Conference - - Lake Street Capital Markets 7 th Annual Best Ideas Growth Conference - MOUNTAIN VIEW, Calif.,
NeuroPace, Inc. (NPCE) Q2 2023 Earnings Call Transcript
10:17am, Friday, 11'th Aug 2023
NeuroPace, Inc. (NASDAQ:NPCE ) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Irina Ridley - Chief Legal Officer and Head of Investor Relations Joel Becker - Chief Exe
NeuroPace to Report Second Quarter 2023 Financial Results on August 8, 2023
04:05pm, Tuesday, 18'th Jul 2023
MOUNTAIN VIEW, Calif., July 18, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, tod
NeuroPace, Inc. (NPCE) CEO Michael Favet on Q1 2023 Results - Earnings Call Transcript
07:42am, Sunday, 07'th May 2023
NeuroPace, Inc. (NASDAQ:NPCE ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Trip Taylor - Gilmartin Group Michael Favet - President & Chief Executive Officer, NeuroPace
NeuroPace to Report First Quarter 2023 Financial Results on May 4, 2023
04:05pm, Monday, 17'th Apr 2023
MOUNTAIN VIEW, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, to
NeuroPace to Present at the 22nd Annual Needham Virtual Healthcare Conference
04:05pm, Monday, 03'rd Apr 2023
MOUNTAIN VIEW, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, to
NeuroPace, Inc. (NPCE) Q4 2022 Earnings Call Transcript
10:21pm, Thursday, 02'nd Mar 2023
NeuroPace, Inc. (NASDAQ:NPCE ) Q4 2022 Results Conference Call March 2, 2023 4:30 PM ET Company Participants Trip Taylor - Gilmartin Group Michael Favet - President, CEO & Director Rebecca Kuhn - CFO,
NeuroPace to Report Fourth Quarter and Full Year 2022 Financial Results on March 2, 2023
08:00am, Friday, 10'th Feb 2023
MOUNTAIN VIEW, Calif., Feb. 10, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, tod
NeuroPace to Present at the 41st Annual J.P. Morgan Healthcare Conference
04:03pm, Wednesday, 21'st Dec 2022
MOUNTAIN VIEW, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, tod
Accelmed Partners Takes Activist Position in NPCE / Neuropace After Q3 Results
01:35am, Wednesday, 23'rd Nov 2022
Fintel reports that Accelmed Partners II L.P.
